A group of scientists has discovered a “more elegant chemotherapy” that can accurately target cancer cells in the fight against the disease.
The research successfully killed cancer cells, while leaving healthy people around them using a technology that relies on DNA editing tools.
Scientists said that this technique has already been used in mice and could be used in the next two years.
Professor Dan Peer, a cancer specialist at Tel Aviv University in Israel, reported that there are “no side effects” and believes that “a cancer cell treated in this way will not reactivate.” Israel time.
“This technology can increase the life expectancy of cancer patients and we hope that one day, will cure the disease.”
The journal was published by scientists from Tel Aviv University, New York University and Harvard Medical School Science advance.
Scientists claim that this is the first time in the world that Crisp genome editing technology, which works by cutting off a portion of DNA, has been used effectively to treat cancer in an animal.
Professor Pir explained that if this technique is used then “we can destroy a tumor” within three treatments because it “can physically cut DNA in cancer cells, and those cells will not survive.” ”
He acknowledged that the technology needed to be “developed more”, but the main point from the current study is that he has shown that it can “kill cancer cells”.
The scientists noted that mice battling cancer had double life expectancy and had a 30 percent higher survival rate than the control group.
Professor Peer stated that once adapted to humans, this treatment can be highly personalized and can be adapted for each patient given, either as a normal injection or a direct injection into a tumor.
For the study, the researchers focused on the two most deadly cancers – metastatic ovarian cancer and glioblastoma, an aggressive type of brain cancer. In glioblastoma, life expectancy and survival rates are usually very low.
But, according to the study, injections against glioblastoma “inhibited tumor growth by 50 percent” and “improved survival by 30 percent”, while in the case of ovarian tumors it “increased survival by 80 percent” Hui.”
“The ability to inhibit gene expression in tumors in vivo opens new avenues for cancer treatment and potential applications for research and targeted gene editing,” the study said.